IP Library › Granted Patent US 8,784,810
Granted Patent B2
US 8,784,810 · App. 13/123,898 · Granted Jul 22, 2014

Treatment of amyloidogenic diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,784,810
App. No.
13/123,898
Granted
Jul 22, 2014
Kind
B2
Abstract

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.

Claims (3)

1. A method of treating Alzheimer's disease, comprising:

subcutaneously administering to a patient having the disease an antibody that specifically binds to an N-terminal fragment of Aβ, wherein the antibody is a humanized antibody comprising three light chain CDRs and three heavy chain CDRs of mouse antibody 3D6 expressed by the hybridoma deposited under ATCC under No. PTA-5130, and wherein the antibody is administered at a dosage within a range of 0.05-0.25 mg/kg and a frequency of between weekly and monthly, thereby treating the patient.

2. The method of claim 1 , wherein the humanized-antibody is bapineuzumab.

Assignments (1)
CHANGE OF NAME Recorded May 5, 2015
From: JANSSEN ALZHEIMER IMMUNOTHERAPY
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035582/0841 →